{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:44:45Z","timestamp":1787906685960,"version":"build-2784847793"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004100","name":"Labex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004100","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006489","name":"Commissariat \u00e0 l'\u00c9nergie Atomique et aux \u00c9nergies Alternatives","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006489","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"ANR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008990","name":"Universit\u00e9 de Lorraine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008990","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015510","name":"Infrastructures en Biologie Sant\u00e9 et Agronomie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012952","name":"Universit\u00e9 Grenoble Alpes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012952","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Vessels, Thrombosis & Hemostasis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bvth.2026.100139","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:49:24Z","timestamp":1768931364000},"page":"100139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Screening chemical libraries for the development of oral treatments for bleeding disorders"],"prefix":"10.1016","volume":"3","author":[{"given":"Renaud","family":"Zelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landry","family":"Seyve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claire","family":"Dagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0999-7751","authenticated-orcid":false,"given":"Caroline","family":"Barette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Coradin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Polack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Jourdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3462-2006","authenticated-orcid":false,"given":"Rapha\u00ebl","family":"Marlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bvth.2026.100139_bib1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.coph.2019.06.005","article-title":"When innovation goes fast. The case of hemophilia","volume":"45","author":"Pilunni","year":"2019","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"10.1016\/j.bvth.2026.100139_bib2","doi-asserted-by":"crossref","first-page":"102696","DOI":"10.1016\/j.rpth.2025.102696","article-title":"Contemporary approaches to treat people with hemophilia: what's new and what's not?","volume":"9","author":"Valentino","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"7","key":"10.1016\/j.bvth.2026.100139_bib3","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","article-title":"Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"22","author":"Madan","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"19","key":"10.1016\/j.bvth.2026.100139_bib4","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1182\/bloodadvances.2023011847","article-title":"Roctavian gene therapy for hemophilia A","volume":"8","author":"Samelson-Jones","year":"2024","journal-title":"Blood Adv"},{"issue":"23","key":"10.1016\/j.bvth.2026.100139_bib5","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1182\/bloodadvances.2024013864","article-title":"Gene therapy for hemophilia","volume":"8","author":"Lenting","year":"2024","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.bvth.2026.100139_bib6","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.ymthe.2025.03.043","article-title":"Gene therapy for hemophilia - from basic science to first approvals of \"One-and-Done\" therapies","volume":"33","author":"Herzog","year":"2025","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.bvth.2026.100139_bib7","doi-asserted-by":"crossref","first-page":"102640","DOI":"10.1016\/j.rpth.2024.102640","article-title":"Gene therapy in hemophilia: the dawn of a new era","volume":"9","author":"Gualtierotti","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"10.1016\/j.bvth.2026.100139_bib8","first-page":"457","article-title":"Non-factor replacement therapy for haemophilia: a current update","volume":"16","author":"Franchini","year":"2018","journal-title":"Blood Transfus"},{"issue":"9","key":"10.1016\/j.bvth.2026.100139_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bvth.2026.100139_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.5582\/ddt.2025.01031","article-title":"Fitusiran: The first approved siRNA therapy for hemophilia via reducing plasma antithrombin levels","volume":"19","author":"Lu","year":"2025","journal-title":"Drug Discov Ther"},{"issue":"22","key":"10.1016\/j.bvth.2026.100139_bib11","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1182\/blood.2019001542","article-title":"Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A\/B with inhibitors: phase 2 trial results","volume":"134","author":"Shapiro","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bvth.2026.100139_bib12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2216455","article-title":"Phase 3 trial of concizumab in hemophilia with inhibitors","volume":"389","author":"Matsushita","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bvth.2026.100139_bib13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.2147\/PPA.S470091","article-title":"The concizumab pen-injector is easy to use and preferred by hemophilia patients and caregivers: a usability study assessing pen-injector handling and preference","volume":"18","author":"Kahr Rasmussen","year":"2024","journal-title":"Patient Prefer Adherence"},{"issue":"5","key":"10.1016\/j.bvth.2026.100139_bib14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jadohealth.2008.06.005","article-title":"A review of adapalene in the treatment of acne vulgaris","volume":"43","author":"Irby","year":"2008","journal-title":"J Adolesc Health"},{"issue":"10","key":"10.1016\/j.bvth.2026.100139_bib15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3390\/pharmaceutics11100490","article-title":"Targeted topical delivery of retinoids in the management of acne vulgaris: current formulations and novel delivery systems","volume":"11","author":"Latter","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bvth.2026.100139_bib16","series-title":"Pharmacology\/Toxicology Review NDA Number 22-502","year":"2009"},{"issue":"2","key":"10.1016\/j.bvth.2026.100139_bib17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J Biomol Screen"},{"issue":"17","key":"10.1016\/j.bvth.2026.100139_bib18","doi-asserted-by":"crossref","first-page":"12203","DOI":"10.1021\/acs.jmedchem.3c00795","article-title":"Design and preclinical characterization program toward asundexian (BAY 2433334), an oral factor XIa inhibitor for the prevention and treatment of thromboembolic disorders","volume":"66","author":"Roehrig","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bvth.2026.100139_bib19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/bs.pmbts.2024.03.013","article-title":"Current progress in high-throughput screening for drug repurposing","volume":"205","author":"Khambhati","year":"2024","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"2","key":"10.1016\/j.bvth.2026.100139_bib20","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.thromres.2013.05.023","article-title":"A serendipitously identified novel small molecule procoagulant compound giving rise to a high-throughput screening assay based on human plasma","volume":"132","author":"Gustafsson","year":"2013","journal-title":"Thromb Res"},{"issue":"4","key":"10.1016\/j.bvth.2026.100139_bib21","doi-asserted-by":"crossref","first-page":"102426","DOI":"10.1016\/j.rpth.2024.102426","article-title":"A small-molecule hemostatic agent for the reversal of direct oral anticoagulant-induced bleeding","volume":"8","author":"Desvages","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"1-3","key":"10.1016\/j.bvth.2026.100139_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"10.1016\/j.bvth.2026.100139_bib23","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/jth.12435","article-title":"Evidence for factor IX-independent roles for factor XIa in blood coagulation","volume":"11","author":"Matafonov","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.bvth.2026.100139_bib24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/ATVBAHA.119.313503","article-title":"Plasma kallikrein contributes to coagulation in the absence of factor XI by activating factor IX","volume":"40","author":"Visser","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.bvth.2026.100139_bib25","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2014810118","article-title":"Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI","volume":"118","author":"Kearney","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.bvth.2026.100139_bib26","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/jth.12295","article-title":"Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates","volume":"11","author":"Puy","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"17","key":"10.1016\/j.bvth.2026.100139_bib27","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-569111","article-title":"Coagulation factor XII in thrombosis and inflammation","volume":"131","author":"Maas","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bvth.2026.100139_bib28","series-title":"Compos\u00e9s chimiques pour le traitement de l'h\u00e9mophilie","author":"Thomas","year":"2021"},{"issue":"1","key":"10.1016\/j.bvth.2026.100139_bib29","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1038\/s41467-021-25888-7","article-title":"Identification of the factor XII contact activation site enables sensitive coagulation diagnostics","volume":"12","author":"Heestermans","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.bvth.2026.100139_bib30","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s11030-022-10440-6","article-title":"Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing","volume":"27","author":"Fidan","year":"2023","journal-title":"Mol Divers"},{"issue":"16","key":"10.1016\/j.bvth.2026.100139_bib31","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.3390\/cancers15164136","article-title":"In silico, in vitro, and in vivo investigations on adapalene as repurposed third generation retinoid against multiple myeloma and leukemia","volume":"15","author":"Boulos","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.bvth.2026.100139_bib32","doi-asserted-by":"crossref","first-page":"e20250049","DOI":"10.1084\/jem.20250049","article-title":"Factor XII-driven coagulation traps bacterial infections","volume":"222","author":"Nickel","year":"2025","journal-title":"J Exp Med"}],"container-title":["Blood Vessels, Thrombosis & Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:20:07Z","timestamp":1779895207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950327226000045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2950327226000045"],"URL":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100139","relation":{},"ISSN":["2950-3272"],"issn-type":[{"value":"2950-3272","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Screening chemical libraries for the development of oral treatments for bleeding disorders","name":"articletitle","label":"Article Title"},{"value":"Blood Vessels, Thrombosis & Hemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100139"}}